S
Investor profile
Investment firm
Deals
12
distinct rounds
Companies
8
backed
Active span
2004–2018
15 yrs
Total round €
€499M
sum of rounds joined
Deals by year
distinct rounds / yearTop sectors
by dealsStages
by dealsCountries
by dealsCo-investment network
shared roundsHover a node for shared-deal counts; click a co-investor to open its profile.
Frequent co-investors
shared rounds- Novo A9
- Essex Woodlands Health Ventures3
- Advent Venture Partners2
- Novartis Venture Fund2
- Aisling Capital1
- Brace Pharma1
- Brightfolk A1
- Gilde Healthcare1
- Growth Foundation1
- Inter-Invest A1
- Life Sciences Partners1
- Merifin Capital1
- Moment A1
- New Enterprise Associates1
- Roos Group AB1
- Sectoral Asset Management1
- Sofinnova Partners1
- Sunstone Capital1
- Takeda Ventures1
- Wellington Partners1
- Zobito1
Portfolio
top 30 by total round €| Company | Country | Rounds | Total € |
|---|---|---|---|
| Symphogen | Denmark | 5 | €254M |
| Adaptimmune | UK | 1 | €95M |
| Merus | Netherlands | 1 | €73M |
| F2G | UK | 1 | €55M |
| NeRRe Therapeutics | UK | 1 | €17M |
| Ivy & Oak | Germany | 1 | €5.0M |
| Learning Bank | Denmark | 1 | €1.8M |
| Chabber | Denmark | 1 | €130k |
Biggest deals
top 10 by amount| Company | Stage | Amount | Date |
|---|---|---|---|
| Symphogen | Series D+ | €100M | 2011-01 |
| Adaptimmune | Series A | €95M | 2014-08 |
| Merus | Series C | €73M | 2015-07 |
| Symphogen | Debt | €68M | 2015-09 |
| F2G | Growth/Late | €55M | 2016-05 |
| Symphogen | Growth/Late | €41M | 2013-04 |
| Symphogen | Series C | €23M | 2004-10 |
| Symphogen | Series D+ | €23M | 2005-12 |
| NeRRe Therapeutics | Series A | €17M | 2012-11 |
| Ivy & Oak | Series A | €5.0M | 2018-07 |